Management

Management

Jan Alenfall, CEO

Jan Alenfall holds a PhD and has over 20 years’ experience from pharmaceutical research and development, for example from research regarding new treatment for immunological diseases and cancer. Alenfall was Head of Pre-clinical and Clinical Development at Bioglan. He has also been Head of Research at Probi AB. Alenfall has solid experience within research, product development, pre-clinical and clinical trials and also in commercial collaborations. In 2006 he was appointed CEO at DermaGen AB. Alenfall has been the author and co-author of 17 publications in scientific journals and has six patent applications.

Jan Alenfall, CEO Follicum

Shares in the company:
Alenfall owns 100 % of Callipa AB, which owns 338 633 shares in Follicum AB.

Alenfall’s other assignments:
Callipa AB: Board Member, CEO

Maria Ekblad, R & D Director

Maria Ekblad has a Masters in Chemistry and more than 20 years’ experience in the pharmaceutical industry. Among these are research and development of new drugs for auto-immune diseases and cancer. In several assignments Maria was in charge of pre-clinical development at Active Biotech as well as their contract research services.

Maria Ekblad, R&D Director Follicum

Shares in the company:
Ekblad owns 13 330 shares in Follicum AB.

Fredrik Werner, CFO

Fredrik Werner holds a BA in Business Administration and has long experience from senior management positions within life sciences and the tech sector. Werner’s previous roles includes CFO at A1M Pharma (now Guard Therapeutics), CEO and CFO at Airsonett AB, CFO at Bonesupport AB and CFO at Netch Technologies AB.

Fredrik_Werner

Shares in the company:
No shares

Werner’s other assignments:

  • FOC Venture AB: Board member, CEO
  • Relationsforum i Skåne AB: Deputy board member